The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction. This severe reaction can occur at any ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...
FDA adds boxed warning to Teva's Copaxone and generic versions after serious allergic reactions, including anaphylaxis that ...
UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...
Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
Already Wednesday morning, the FDA sent out a communication about a safety warning added to the multiple sclerosis drug ...
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...
The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback